X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Proceeds drawn by LIDDS under the convertible notes agreement will be used to further advance the project in clinical development, creating a solid foundation for new partnerships and license agreements for Liproca, based on the NanoZolid® technology.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Liproca
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nice & Green
Deal Size: $4.3 million Upfront Cash: Undisclosed
Deal Type: Financing February 22, 2022
Details:
The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Liproca Depot
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
In patients who received a second Liproca® Depot injection (6 of 12), at 2 months post treatment, PSA levels were in average reduced by 28 %.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Liproca Depot
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Final data from the LPC-004 study confirms Liproca® Depot’s potential as a safe and effective anti-androgen treatment for prostate cancer patients that currently are not treated but kept under ‘Active Surveillance’.
Lead Product(s): 2-Hydroxyflutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
